Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and specialty services to the worldwide biopharmaceuticals, cosmetics, nutraceuticals, agrochem, and food & beverage industries, is reporting its financial results for Q1 2022, the period ended March 31, 2022; the company also released a business update provided guidance for the remainder of the year. Key numbers from the report include total revenue for the quarter totaling $480,000, down 14% from $560,000 for Q1 2021; instrument sales of $465,000, compared to $553,800 for Q1 2021; and consumable sales for the quarter reached $40,000, a decrease of 61% from the same period last year. Operational highlights for the company include the announcement of PBIO’s first nanoemulsions manufacturing agreement under its new UST Early Access Program; the announcement of the Early Access Program for UST nanoemulsion processing; the successful commissioning by The Ohio State University (“OSU”) of PBI’s production-scale BaroShear UST MAX System for better processing of liquid foods and beverages within its College of Food, Agriculture and Environmental Sciences; and the installation of the company’s UST platform in OSU’s Advanced Food Processing Technology Pilot Plant. “Driven by demand from current and prospective customers, and integrating with our plan for the UST platform to be ready for broad-scale commercialization in 2023, we announced the release of an Early Access Program for our UST processing platform late last month,” said PBI president and CEO Richard T. Schumacher in the press release. “In just two weeks since that announcement, we have (i) executed the first-ever agreement to manufacture product for sale using our revolutionary UST platform for the preparation of high-quality nanoemulsions; (ii) initiated negotiations with several additional groups for UST processing projects to begin this year (initially in the nutraceutical and cosmetics areas); (iii) begun to develop and expand the capabilities needed for a successful commercial launch, including upgrades in manufacturing, quality control, project management, and logistics; and (iv) started to supplement our technical, sales, and marketing areas. With current first strides and announcements of initial commercialization activities and agreements for our UST platform, our team and commercial partners are becoming palpably excited. . . . The company expects to be profitable and cash-flow positive by the end of 2023.”
To view the full press release, visit https://ibn.fm/2qGKN
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented-enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control biomolecular interactions (e.g., cell lysis, biomolecule extraction). The company’s primary focus is on the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of PBIO’s pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit the company website at www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
